Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Exjade, Jadenu, Desirox
Deferasirox is an oral iron chelator used to reduce chronic iron overload due to blood transfusions. It belongs to the class of tridentate iron chelators and works by binding to iron in the bloodstream, allowing it to be excreted by the kidneys. This helps prevent the damage caused by excess iron deposition in organs like the liver, heart, and endocrine glands.
For reducing chronic iron overload caused by frequent blood transfusions.
Deferasirox has been associated with serious adverse reactions, including kidney failure, liver failure, and gastrointestinal hemorrhage. Patients should be monitored closely for these events.
Outcome:
Increased midazolam levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Increased theophylline levels
Mechanism:
Inhibition of CYP1A2
Outcome:
No clinically significant interaction
Mechanism:
None known
Most likely new formulation: extended-release formulation (Year: 2026, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood of deferasirox maintaining its approved status for iron overload.
Iron Chelator
Triazole